Perinatal tissues and cells in tissue engineering and regenerative medicine

Deus, Inês A.; Mano, João F.; Custódio, Catarina A.

doi:10.1016/j.actbio.2020.04.035

Cited by 50 publications

(43 citation statements)

References 175 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, the use of different proteins for recapitulating the TME is still poorly explored. Human‐derived proteins, such as the ones obtained from perinatal tissues [ 289 ] or from human blood plasma, [ 290 ] could be a very interesting source of biomaterials to produce humanized structures in cancer models. Moreover, recent advances genetic engineering tools for producing synthetic proteins such as recombinant elastins is another valuable alternative to produce proteinaceous hydrogels with tunable properties that can be valuable for 3D in vitro tumor modeling.…”

Section: Future Perspectives and Concluding Remarksmentioning

confidence: 99%

Proteinaceous Hydrogels for Bioengineering Advanced 3D Tumor Models

et al. 2021

Self Cite

View full text Add to dashboard Cite

The establishment of tumor microenvironment using biomimetic in vitro models that recapitulate key tumor hallmarks including the tumor supporting extracellular matrix (ECM) is in high demand for accelerating the discovery and preclinical validation of more effective anticancer therapeutics. To date, ECM‐mimetic hydrogels have been widely explored for 3D in vitro disease modeling owing to their bioactive properties that can be further adapted to the biochemical and biophysical properties of native tumors. Gathering on this momentum, herein the current landscape of intrinsically bioactive protein and peptide hydrogels that have been employed for 3D tumor modeling are discussed. Initially, the importance of recreating such microenvironment and the main considerations for generating ECM‐mimetic 3D hydrogel in vitro tumor models are showcased. A comprehensive discussion focusing protein, peptide, or hybrid ECM‐mimetic platforms employed for modeling cancer cells/stroma cross‐talk and for the preclinical evaluation of candidate anticancer therapies is also provided. Further development of tumor‐tunable, proteinaceous or peptide 3D microtesting platforms with microenvironment‐specific biophysical and biomolecular cues will contribute to better mimic the in vivo scenario, and improve the predictability of preclinical screening of generalized or personalized therapeutics.

show abstract

Section: Future Perspectives and Concluding Remarksmentioning

confidence: 99%

Proteinaceous Hydrogels for Bioengineering Advanced 3D Tumor Models

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…Bone marrow was the first source of MSCs but adipose tissue is currently one of the most used. In addition, perinatal derivatives [10] like the placental membranes [54,55] and the umbilical cord are considered clinical waste material, and together with the amniotic fluid are great resources [56] for the isolation of immunotolerant and immunomodulating [57] stem cells, including MSCs [58]. MSC isolation does not raise ethical issues; they are non-tumorigenic in vivo and are a well-tolerated medicinal tool suitable [59] for cell therapy purposes.…”

Section: Mscs As Source Of Antibiotic-free Nanomaterialsmentioning

confidence: 99%

Microfluidic Tools for Enhanced Characterization of Therapeutic Stem Cells and Prediction of Their Potential Antimicrobial Secretome

Marrazzo

Pizzuti

Zia³

et al. 2021

Antibiotics

View full text Add to dashboard Cite

Antibiotic resistance is creating enormous attention on the development of new antibiotic-free therapy strategies for bacterial diseases. Mesenchymal stromal stem cells (MSCs) are the most promising candidates in current clinical trials and included in several cell-therapy protocols. Together with the well-known immunomodulatory and regenerative potential of the MSC secretome, these cells have shown direct and indirect anti-bacterial effects. However, the low reproducibility and standardization of MSCs from different sources are the current limitations prior to the purification of cell-free secreted antimicrobial peptides and exosomes. In order to improve MSC characterization, novel label-free functional tests, evaluating the biophysical properties of the cells, will be advantageous for their cell profiling, population sorting, and quality control. We discuss the potential of emerging microfluidic technologies providing new insights into density, shape, and size of live cells, starting from heterogeneous or 3D cultured samples. The prospective application of these technologies to studying MSC populations may contribute to developing new biopharmaceutical strategies with a view to naturally overcoming bacterial defense mechanisms.

show abstract

“…In addition, it restored a normal lung tissue-to-air space ratio, reduced pro-inflammatory cytokines (145), normalized secondary septal crests, reduced collagen and elastin deposition and fibrosis (144). Deus et al (152) described hAECs having beneficial effects by the production and secretion of various bioactive factors involved in anti-inflammation, immunomodulation, wound healing, angiogenesis, anti-fibrosis and anti-bacterial (152).…”

Section: Human Amniotic Epithelial Cells (Haecs)mentioning

confidence: 99%

A Review of Placenta and Umbilical Cord-Derived Stem Cells and the Immunomodulatory Basis of Their Therapeutic Potential in Bronchopulmonary Dysplasia

et al. 2021

View full text Add to dashboard Cite

Bronchopulmonary dysplasia (BPD) is a devastating lung disorder of preterm infants as a result of an aberrant reparative response following exposures to various antenatal and postnatal insults. Despite sophisticated medical treatment in this modern era, the incidence of BPD remains unabated. The current strategies to prevent and treat BPD have met with limited success. The emergence of stem cell therapy may be a potential breakthrough in mitigating this complex chronic lung disorder. Over the last two decades, the human placenta and umbilical cord have gained increasing attention as a highly potential source of stem cells. Placenta-derived stem cells (PDSCs) and umbilical cord-derived stem cells (UCDSCs) display several advantages such as immune tolerance and are generally devoid of ethical constraints, in addition to their stemness qualities. They possess the characteristics of both embryonic and mesenchymal stromal/stem cells. Recently, there are many preclinical studies investigating the use of these cells as therapeutic agents in neonatal disease models for clinical applications. In this review, we describe the preclinical and clinical studies using PDSCs and UCDSCs as treatment in animal models of BPD. The source of these stem cells, routes of administration, and effects on immunomodulation, inflammation and regeneration in the injured lung are also discussed. Lastly, a brief description summarized the completed and ongoing clinical trials using PDSCs and UCDSCs as therapeutic agents in preventing or treating BPD. Due to the complexity of BPD, the development of a safe and efficient therapeutic agent remains a major challenge to both clinicians and researchers.

show abstract

Perinatal tissues and cells in tissue engineering and regenerative medicine

Cited by 50 publications

References 175 publications

Proteinaceous Hydrogels for Bioengineering Advanced 3D Tumor Models

Proteinaceous Hydrogels for Bioengineering Advanced 3D Tumor Models

Microfluidic Tools for Enhanced Characterization of Therapeutic Stem Cells and Prediction of Their Potential Antimicrobial Secretome

A Review of Placenta and Umbilical Cord-Derived Stem Cells and the Immunomodulatory Basis of Their Therapeutic Potential in Bronchopulmonary Dysplasia

Contact Info

Product

Resources

About